GP 1636 / Sequence
Box Sequence
PATENT
Customer Number 22,852
Attorney Docket No. 03806.0448

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	**RECEIVED**
Joel CROUZET *et al.*	)	Group Art Unit: 1636
	)	MAR 1 2 2002
Serial No.: 09/369,883	)	Examiner: W. Sandals TECH CENTER 1600/2900
	)	
Filed: August 9, 1999	)	
	)	**Hand Carry to Group 1600**
For: FORMULATION OF STABILIZED	)	**ATTENTION: W. SANDALS**
CATIONIC TRANSFECTION	)	
AGENTS(S)/NUCLEIC ACID	)	
PARTICLES	)	

#12E
3 dta
3-13-02

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Amendment and Statement Under 37 C.F.R. § § 1.821 - 1.825

In response to the Raw Sequence Listing Error Summary dated January 2, 2002,

(copy enclosed) Applicants submit the attached Substitute Sequence Listing, and

request amendment of the present specification by replacing the original Sequence

Listing with the Substitute Sequence Listing filed herewith.

The undersigned states that the content of the substitute paper copy and the

substitute computer readable copy of the Sequence Listing, filed March 6, 2002, are the

same, contain no new matter, and conform with Patent and Trademark Office

requirements for the Sequence Listing in accordance with 37 C.F.R. §§1.821-1.825.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Dated: March 6, 2002

By:_____
Charles D. Niebylski
Reg. No. 46,116
(202) 408-4128

New Sequence Listing Error Summary

ERROR DETECTED   **SUGGESTED CORRECTION**   SERIAL NUMBER: _09/369,883_

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 _____ Wrapped Nucleics

The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".

2 _____ Wrapped Aminos

The amino acid number/text at the end of each line "wrapped " down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".

3 _____ Incorrect Line Length

The rules require that a line not exceed 72 characters in length. This includes spaces.

4 _____ Misaligned Amino Acid Numbering

The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
between the numbering. It is recommended to delete any tabs and use spacing between the numbers.

5 _____ Non-ASCII

This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.

6 _____ Variable Length

Sequence(s) _____ contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) feature section that some may be missing.

7 _____ Patentln ver. 2.0 "bug"

A "bug" in Patentln version 2.0 has caused the <220>-<223> section to be missing from amino acid
sequence(s) _____. Normally, Patentln would automatically generate this section from the
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223>
sections for Artificial or Unknown sequences.

8 _____ Skipped Sequences (OLD RULES)

Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).

9 _____ Skipped Sequences (NEW RULES)

Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

10 _____ Use of n's or Xaa's (NEW RULES)

Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

11 _____ Use of "Artificial" (NEW RULES)

Use of "Artificial" only as "<213> Organism" response is incomplete, per 1,823(b) of New Sequence Rules.
Valid response is Artificial Sequence.

12 ✓ Use of <220>Feature (NEW RULES)

Sequence(s) _1+2_ are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial Sequence" or "Unknown"
Please explain source of genetic material in <220> to <223> section.

(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of new Rules)

13 _____ Patentln ver. 2.0 "bug"

Please do not use "Copy to Disk" function of Patentln version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

AMC - Biotechnology Systems Branch - 4/06/2001

1636

RAW SEQUENCE LISTING   DATE: 05/01/2001
PATENT APPLICATION: US/09/369,883   TIME: 14:26:47

                                                                   Does Not Comply
Input Set : A:\es.txt   Corrected Diskette Needed
Output Set: N:\CRF3\05012001\I369883.raw

```
 3 <110> APPLICANT: Crouzet, Joel
 4         Pitard, Bruno
 6 <120> TITLE OF INVENTION: Formulation of Stabilised Cationic Transfection Agent(s)/Nucleic Acid
 7         Particles
 9 <130> FILE REFERENCE: 3806.0448
11 <140> CURRENT APPLICATION NUMBER: 09/369,883
12 <141> CURRENT FILING DATE: 1999-08-09
14 <150> PRIOR APPLICATION NUMBER: PCT/FR98/00222
15 <151> PRIOR FILING DATE: 1998-02-06
17 <150> PRIOR APPLICATION NUMBER: FR97/01,467
18 <151> PRIOR FILING DATE: 1997-02-10
20 <160> NUMBER OF SEQ ID NOS: 2
22 <170> SOFTWARE: PatentIn version 3.0
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 9
26 <212> TYPE: PRT
27 <213> ORGANISM: Artificial sequence
```

W--> 29 <220> FEATURE:
W--> 29 <223> OTHER INFORMATION:

```
29 <400> SEQUENCE: 1
31 Lys Thr Pro Lys Lys Ala Lys Lys Pro
32 1               5
34 <210> SEQ ID NO: 2
35 <211> LENGTH: 8
36 <212> TYPE: PRT
37 <213> ORGANISM: Artificial sequence
```

W--> 38 <220> FEATURE:
W--> 39 <223> OTHER INFORMATION:

```
39 <400> SEQUENCE: 2
41 Ala Thr Pro Ala Lys Lys Ala Ala
42 1               5
```

RECEIVED

MAR 1 2 2002

TECH CENTER 1600/2900

*Missing mandatory <220>, <223>
features to explain the source
of the artificial sequences.
See #12 on the Error
Summary Sheet.*

VERIFICATION SUMMARY   DATE: 05/01/2001
PATENT APPLICATION: US/09/369,883   TIME: 14:26:48

Input Set : A:\es.txt
Output Set: N:\CRF3\05012001\I369883.raw

```
L:29 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:29 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:39 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:39 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
```